Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia

American Journal of Hematology

Volumn 86, Issue 3, 2011, Pages 267-272

  Kiser, Tyree H ^a   Mann, Allison M ^b   Trujillo, Toby C ^a   Hassell, Kathryn L ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN; HIRULOG; THROMBIN INHIBITOR;

ADULT; ARTICLE; BLEEDING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG FATALITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PARTIAL THROMBOPLASTIN TIME; PHYSICIAN; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTITHROMBINS; EMPIRICAL RESEARCH; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 79951896637     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21955     Document Type: Article

References (22)

1. Crowther MA, Cook DJ, Albert M, et al. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 2010; 25: 287-293.
2. Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-1708.
3. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008; 133: 340S-380S.
4. Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997; 56: 12-16.
5. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999; 99: 73-80.
6. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-associated thrombocytopenia study (HAT) investigators. Circulation 1999; 100: 587-593.
7. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia-Results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3: 2428-2436.
8. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843.
9. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163: 1849-1856.
10. Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2006; 26: 461-468.
11. Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2008; 28: 1115-1124.
12. Saugel B, Phillip V, Moessmer G, et al. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: A retrospective study. Crit Care 2010; 14: R90.
13. Linnemann B, Greinacher A, Lindhoff-Last E. Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease. Vasa 2010; 39: 103-107.
14. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006; 26: 452-460.
15. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993; 119: 874-881.
16. Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005; 25: 1736-1745.
17. Smythe MA, Koerber JM, Forsyth LL, et al. Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. Pharmacotherapy 2009; 29: 1073-1081.
18. Ansara AJ, Arif S, Warhurst RD. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2009; 43: 9-18.
19. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2: 148-157.
20. Pouplard C, Gueret P, Fouassier M, et al. Prospective evaluation of the "4Ts" score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007; 5: 1373-1379.
21. Bernardi E, Piccioli A, Oliboni G, et al. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism-An overview. Thromb Haemost 2000; 84: 22-26.
22. Elliott CG, Hiltunen SJ, Suchyta M, et al. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med 1994; 154: 999-1004.